Showing results 16 to 17 of 17
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
2020 | |||
When compared to plasma‐based detection, osimertinib‐treated non‐small cell lung cancer (NSCLC) with tissue rebiopsy‐confirmed acquired T790M mutation is associated with better survival Journal:Asia-Pacific Journal of Clinical Oncology | 2021 |